| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1084251217 |
| P356 | DOI | 10.1186/S12936-017-1766-3 |
| P8608 | Fatcat ID | release_t6cd6t3uabbsrmobxkruut34tm |
| P932 | PMC publication ID | 5347822 |
| P698 | PubMed publication ID | 28288639 |
| P50 | author | Christopher J Genito | Q60045312 |
| Philippe Saudan | Q105045974 | ||
| Timothy W Phares | Q117769739 | ||
| P2093 | author name string | Norman C Waters | |
| Sheetij Dutta | |||
| Michael D Porter | |||
| Farhat A Khan | |||
| Anthony D May | |||
| Margot DeBot | |||
| Nathan A Hoyt | |||
| P2860 | cites work | Transgenic rodent Plasmodium berghei parasites as tools for assessment of functional immunogenicity and optimization of human malaria vaccines | Q21032495 |
| Evolutionary and Biomedical Insights from the Rhesus Macaque Genome | Q22065872 | ||
| Species-specific recognition of single-stranded RNA via toll-like receptor 7 and 8 | Q24310398 | ||
| Protection against malaria by immunization with plasmid DNA encoding circumsporozoite protein | Q24563514 | ||
| Kinetics and isotype profile of antibody responses in rhesus macaques induced following vaccination with HPV 6, 11, 16 and 18 L1-virus-like particles formulated with or without Merck aluminum adjuvant | Q24802323 | ||
| Rhesus macaque antibody molecules: sequences and heterogeneity of alpha and gamma constant regions | Q27478005 | ||
| The crystal structure of bacteriophage Q beta at 3.5 A resolution | Q27733257 | ||
| Protection against malaria at 1 year and immune correlates following PfSPZ vaccination | Q28049695 | ||
| Paleontological evidence to date the tree of life | Q28268884 | ||
| Safety and immunogenicity of multi-antigen AMA1-based vaccines formulated with CoVaccine HTTM and Montanide ISA 51 in rhesus macaques | Q28742239 | ||
| Function of region I and II adhesive motifs of Plasmodium falciparum circumsporozoite protein in sporozoite motility and infectivity | Q30039112 | ||
| Safety and immunogenicity of a virus-like particle pandemic influenza A (H1N1) 2009 vaccine: results from a double-blinded, randomized Phase I clinical trial in healthy Asian volunteers. | Q30364932 | ||
| The phylogeny of rodent malaria parasites: simultaneous analysis across three genomes | Q33246318 | ||
| A vaccine against nicotine for smoking cessation: a randomized controlled trial | Q33346321 | ||
| Blood stage malaria vaccine eliciting high antigen-specific antibody concentrations confers no protection to young children in Western Kenya | Q33415066 | ||
| Evaluation of RTS,S/AS02A and RTS,S/AS01B in adults in a high malaria transmission area. | Q33489512 | ||
| Transgenic parasites stably expressing full-length Plasmodium falciparum circumsporozoite protein as a model for vaccine down-selection in mice using sterile protection as an endpoint | Q34036184 | ||
| Protective CD8+ T lymphocytes in primates immunized with malaria sporozoites | Q34166294 | ||
| Roles of the amino terminal region and repeat region of the Plasmodium berghei circumsporozoite protein in parasite infectivity | Q34185908 | ||
| Live attenuated malaria vaccine designed to protect through hepatic CD8⁺ T cell immunity | Q34214786 | ||
| A full-length Plasmodium falciparum recombinant circumsporozoite protein expressed by Pseudomonas fluorescens platform as a malaria vaccine candidate | Q34232909 | ||
| Baculovirus-vectored multistage Plasmodium vivax vaccine induces both protective and transmission-blocking immunities against transgenic rodent malaria parasites | Q34298647 | ||
| Simple Centrifugation Method for Rapid Separation of Sporozoites from Mosquitoes | Q44164986 | ||
| A chemiluminescent-western blot assay for quantitative detection of Plasmodium falciparum circumsporozoite protein | Q44168334 | ||
| Pre-clinical evaluation of new adjuvant formulations to improve the immunogenicity of the malaria vaccine RTS,S/AS02A. | Q44169635 | ||
| The use of transgenic Plasmodium berghei expressing the Plasmodium vivax antigen P25 to determine the transmission-blocking activity of sera from malaria vaccine trials | Q44170388 | ||
| A preliminary evaluation of a recombinant circumsporozoite protein vaccine against Plasmodium falciparum malaria. RTS,S Malaria Vaccine Evaluation Group | Q44174498 | ||
| Immunisation with recombinant AMA-1 protects mice against infection with Plasmodium chabaudi | Q44994461 | ||
| Universal vaccine against influenza virus: linking TLR signaling to anti-viral protection | Q45358078 | ||
| A vaccine for hypertension based on virus-like particles: preclinical efficacy and phase I safety and immunogenicity | Q45409539 | ||
| Evaluation of the safety and immunogenicity of Plasmodium falciparum apical membrane antigen 1, merozoite surface protein 1 or RTS,S vaccines with adjuvant system AS02A administered alone or concurrently in rhesus monkeys. | Q47917346 | ||
| Protection against malaria by immunization with a Plasmodium yoelii circumsporozoite protein nucleic acid vaccine | Q48007496 | ||
| Immunization against malaria with a recombinant protein. | Q48011727 | ||
| CpG oligodeoxynucleotides as vaccine adjuvants in primates | Q77584362 | ||
| Protection against malaria by intravenous immunization with a nonreplicating sporozoite vaccine | Q34362872 | ||
| IgG2 antibodies against a clinical grade Plasmodium falciparum CSP vaccine antigen associate with protection against transgenic sporozoite challenge in mice | Q34400813 | ||
| First case of a naturally acquired human infection with Plasmodium cynomolgi | Q34406410 | ||
| Poly(I:C) is an effective adjuvant for antibody and multi-functional CD4+ T cell responses to Plasmodium falciparum circumsporozoite protein (CSP) and αDEC-CSP in non human primates | Q34416103 | ||
| Fractional Third and Fourth Dose of RTS,S/AS01 Malaria Candidate Vaccine: A Phase 2a Controlled Human Malaria Parasite Infection and Immunogenicity Study | Q34530710 | ||
| The malaria circumsporozoite protein has two functional domains, each with distinct roles as sporozoites journey from mosquito to mammalian host | Q34577701 | ||
| Malaria infection by sporozoite challenge induces high functional antibody titres against blood stage antigens after a DNA prime, poxvirus boost vaccination strategy in Rhesus macaques | Q34615872 | ||
| The relationship between RTS,S vaccine-induced antibodies, CD4⁺ T cell responses and protection against Plasmodium falciparum infection | Q34684347 | ||
| Randomized, double-blind, phase 2a trial of falciparum malaria vaccines RTS,S/AS01B and RTS,S/AS02A in malaria-naive adults: safety, efficacy, and immunologic associates of protection | Q34990090 | ||
| Bacterially produced recombinant influenza vaccines based on virus-like particles | Q35048127 | ||
| A field trial to assess a blood-stage malaria vaccine | Q35622737 | ||
| Ad35.CS.01-RTS,S/AS01 Heterologous Prime Boost Vaccine Efficacy against Sporozoite Challenge in Healthy Malaria-Naïve Adults | Q35684141 | ||
| Priming with an adenovirus 35-circumsporozoite protein (CS) vaccine followed by RTS,S/AS01B boosting significantly improves immunogenicity to Plasmodium falciparum CS compared to that with either malaria vaccine alone | Q35784197 | ||
| Head-to-Head Comparison of Soluble vs. Qβ VLP Circumsporozoite Protein Vaccines Reveals Selective Enhancement of NANP Repeat Responses | Q35841913 | ||
| Phase 1/2a Trial of Plasmodium vivax Malaria Vaccine Candidate VMP001/AS01B in Malaria-Naive Adults: Safety, Immunogenicity, and Efficacy | Q35937418 | ||
| Proteolytic Cleavage of the Plasmodium falciparum Circumsporozoite Protein Is a Target of Protective Antibodies | Q36024455 | ||
| Chemoprophylaxis with sporozoite immunization in P. knowlesi rhesus monkeys confers protection and elicits sporozoite-specific memory T cells in the liver | Q36275670 | ||
| Full-length Plasmodium falciparum circumsporozoite protein administered with long-chain poly(I·C) or the Toll-like receptor 4 agonist glucopyranosyl lipid adjuvant-stable emulsion elicits potent antibody and CD4+ T cell immunity and protection in mi | Q36646698 | ||
| Human studies with synthetic peptide sporozoite vaccine (NANP)3-TT and immunization with irradiated sporozoites | Q36668519 | ||
| Clinical trial in healthy malaria-naïve adults to evaluate the safety, tolerability, immunogenicity and efficacy of MuStDO5, a five-gene, sporozoite/hepatic stage Plasmodium falciparum DNA vaccine combined with escalating dose human GM-CSF DNA | Q36694820 | ||
| Safety, immunogenicity, and efficacy of a Plasmodium falciparum vaccine comprising a circumsporozoite protein repeat region peptide conjugated to Pseudomonas aeruginosa toxin A | Q36944687 | ||
| Development of a chimeric Plasmodium berghei strain expressing the repeat region of the P. vivax circumsporozoite protein for in vivo evaluation of vaccine efficacy | Q37036065 | ||
| Enhanced immunogenicity of Plasmodium falciparum peptide vaccines using a topical adjuvant containing a potent synthetic Toll-like receptor 7 agonist, imiquimod | Q37075435 | ||
| Mechanisms of protective immune responses induced by the Plasmodium falciparum circumsporozoite protein-based, self-assembling protein nanoparticle vaccine | Q37151766 | ||
| Protective humoral immunity elicited by a needle-free malaria vaccine comprised of a chimeric Plasmodium falciparum circumsporozoite protein and a Toll-like receptor 5 agonist, flagellin | Q37336064 | ||
| Efficacy of a Plasmodium vivax malaria vaccine using ChAd63 and modified vaccinia Ankara expressing thrombospondin-related anonymous protein as assessed with transgenic Plasmodium berghei parasites | Q37643867 | ||
| Vaccine delivery: a matter of size, geometry, kinetics and molecular patterns | Q37800358 | ||
| Therapeutic vaccines for chronic diseases: successes and technical challenges | Q37926764 | ||
| A malaria vaccine for travelers and military personnel: Requirements and top candidates | Q39517141 | ||
| Anti-IgE Qb-VLP Conjugate Vaccine Self-Adjuvants through Activation of TLR7. | Q39581494 | ||
| Generation of Transgenic Rodent Malaria Parasites Expressing Human Malaria Parasite Proteins | Q40960433 | ||
| Comparison of the immune responses induced by soluble and particulate Plasmodium vivax circumsporozoite vaccine candidates formulated in AS01 in rhesus macaques | Q42260871 | ||
| Merozoite surface protein 1 of Plasmodium vivax induces a protective response against Plasmodium cynomolgi challenge in rhesus monkeys | Q43013555 | ||
| Safety and efficacy of a recombinant DNA Plasmodium falciparum sporozoite vaccine | Q44148667 | ||
| Cutting edge: a new tool to evaluate human pre-erythrocytic malaria vaccines: rodent parasites bearing a hybrid Plasmodium falciparum circumsporozoite protein | Q44149714 | ||
| Functional immunogenicity of baculovirus expressing Pfs25, a human malaria transmission-blocking vaccine candidate antigen | Q44153250 | ||
| P433 | issue | 1 | |
| P921 | main subject | malaria | Q12156 |
| Macaca | Q177601 | ||
| malaria vaccine | Q6741353 | ||
| P304 | page(s) | 115 | |
| P577 | publication date | 2017-03-13 | |
| P1433 | published in | Malaria Journal | Q15749954 |
| P1476 | title | Rhesus macaque and mouse models for down-selecting circumsporozoite protein based malaria vaccines differ significantly in immunogenicity and functional outcomes | |
| P478 | volume | 16 |
| Q38735533 | Liposomes containing monophosphoryl lipid A and QS-21 serve as an effective adjuvant for soluble circumsporozoite protein malaria vaccine FMP013. |
| Q92976912 | Optimization of a Plasmodium falciparum circumsporozoite protein repeat vaccine using the tobacco mosaic virus platform |
| Q57299517 | Overcoming immunogenicity issues of HIV p24 antigen by the use of innovative nanostructured lipid carriers as delivery systems: evidences in mice and non-human primates |
| Q99635796 | Quantification of Plasmodium knowlesi versus Plasmodium falciparum in the rhesus liver: implications for malaria vaccine studies in rhesus models |
| Q94953008 | Safety and immunogenicity of a recombinant vaccine against Trypanosoma cruzi in Rhesus macaques |
| Q92449403 | Safety, toxicity and immunogenicity of a malaria vaccine based on the circumsporozoite protein (FMP013) with the adjuvant army liposome formulation containing QS21 (ALFQ) |
| Q92417363 | The current state of animal models and genomic approaches towards identifying and validating molecular determinants of Mycobacterium tuberculosis infection and tuberculosis disease |
Search more.